Editas Medicine is a biotechnology and synthetic biology company using genetic engineering to create therapeutics for treating disease that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Feng Zhang, J. Keith Joung, and Jennifer A. Doudna.
Editas Medicine has developed a proprietary genome editing platform based on CRISPR using different engineered variants of CRISPR effector nucleases Cas9 and Cpf1 (also known as Cas12a). The company is working on editing efficiency, control of cutting and delivery of treatment to sight of disease. Editas Medicine is in the discovery stage of developing CRISPR gene edit treatments for the following conditions:
Leber Congenital Amaurosis 10
Usher Syndrome 2a
T Cells for cancer treatments
Alpha-I Antitrypsin Deficiency
Editas Medicine was previously founded under the name Gengine by Feng Zhang, George Church, Keith Joung, David Liu all from The Broad Institute at MIT and Harvard along with Jennifer Doudna from University of California, Berkeley. Jennifer Doudna left and co-founded Intellia Therapeutics.
Andrew Hack, M.D., Ph.D.
Charlene Stern, J.D., Ph.D.
Vice President and Head of Legal
Charles Albright, Ph.D.
Vice President and Head of Human Resources
Timothy D. Hunt, J.D.
Senior Vice President of Corporate Affairs
Vic Myer, Ph.D.
Chief Technology Officer
Documentaries, videos and podcasts
- CRISPR/Cas ToolsClustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) proteins perform adaptive immune functions in prokaryotic organisms defending against foreign nucleic acids such as viruses. CRISPR/Cas tools have been adapted for use in genome editing and other DNA and RNA targeting applications.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Synthetic biologyA cluster of topics related to synthetic biology.
- CRISPRClustered regularly interspaced short palindromic repeats (CRISPR) is a prokaryotic adaptive immune response that provides immunity against foreign nucleic acids, such as viral DNA and bacterial plasmids, through the use of crRNAs (CRISPR RNAs) and associated Cas genes.
- CRISPR-Cas9CRISPR-Cas9 is a genome editing system. CRISPR systems provides immunity to bacteria and archaea from viruses and has been adapted for use as a genome editing tool capable of knocking out genes and rewriting genetic sequences in animal, plant and fungi. CRISPR-Cas9 is being adapted to other applications outside genome editing.
- CRISPR-Cas12aCRISPR-Cas12a is is a genome editing tool similar to CRISPR-Cas9. CRISPR-Cas12a is a set of RNA guided DNA targeting proteins capable of producing targeted double-stranded DNA (dsDNA) breaks, targeted single-stranded DNA breaks, and indiscriminate ssDNA degradation in trans. The effector protein Cas12a is also known at Cpf1.
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Synthetic biologyInterdisciplinary branch of biology and engineering, applying multiple disciplines to build artificial biological systems for research, engineering, and medical applications.